REGN Stock Performance, Insider Transaction and News

REGN - Regeneron Pharmaceuticals, Inc.

Market Cap	80.32B	P/E	19.87	EPS this Y	2.80%	Ern Qtrly Grth	-3.10%
Income	3.95B	Forward P/E	17.49	EPS next Y	5.70%	50D Avg Chg	-1.00%
Sales	13.12B	PEG	2.74	EPS past 5Y	17.46%	200D Avg Chg	-3.00%
Dividend	N/A	Price/Book	3.34	EPS next 5Y	7.36%	52W High Chg	-13.00%
Recommedations	2.00	Quick Ratio	4.82	Shares Outstanding	107.94M	52W Low Chg	28.00%
Insider Own	2.58%	ROA	8.49%	Shares Float	102.75M	Beta	0.14
Inst Own	89.30%	ROE	16.26%	Shares Shorted/Prior	1.39M/1.39M	Price	732.12
Gross Margin	52.32%	Profit Margin	30.14%	Avg. Volume	638,883	Target Price	1,048.72
Oper. Margin	29.20%	Earnings Date	May 2	Volume	606,072	Change	-0.94%

Healthcare | Biotechnology | United States

About Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Regeneron Pharmaceuticals, Inc. News

09:02 AM	Regeneron (REGN) Reports Next Week: What You Should Expect
07:44 AM	UPDATE 1-AbbVie's skin disease drug found to be more effective than Regeneron's Dupixent in study
07:44 AM	The Zacks Analyst Blog Highlights Danaher, Regeneron Pharmaceuticals, Palo Alto Networks, Workday and American Electric Power
06:00 AM	Regeneron to collaborate on gene editing therapies with Doudna-founded Mammoth
06:00 AM	Regeneron and Mammoth Biosciences Collaborate to Pursue Next-Generation CRISPR-Based Gene Editing for Multiple Diseases
02:00 AM	Regeneron expands in gene editing with Mammoth deal
04/24/24	Top Stock Reports for Danaher, Regeneron Pharmaceuticals & Palo Alto Networks
04/24/24	Regeneron to Showcase Progress in Advancing Novel Investigational Treatment Approaches for a Broad Range of Solid Tumors and Blood Cancers at ASCO
04/22/24	Regeneron to Highlight Advances in Genetic Medicine Research at American Society of Gene and Cell Therapy (ASGCT)
04/22/24	Agenus (AGEN) Soars 6.8%: Is Further Upside Left in the Stock?
04/19/24	Regeneron Pharmaceuticals Insiders Sell US$26m Of Stock, Possibly Signalling Caution
04/18/24	Biotech Stock Roundup: REGN, SAGE, NMRA Down on Updates, ITCI Gains on Study Success
04/17/24	Why Investors Need to Take Advantage of These 2 Medical Stocks Now
04/16/24	Why Regeneron (REGN) Could Beat Earnings Estimates Again
04/15/24	UPDATE 1-Regeneron to defend against DOJ complaint on drug-price manipulation
04/15/24	Regeneron to defend against DOJ complaint on drug-price manipulation
04/15/24	Regeneron to defend US Justice Department's complaint on drug-pricing manipulation
04/15/24	Regeneron commits $500M to new venture capital fund
04/15/24	Antitrust fervor is gripping Washington and Silicon Valley. But lawsuits have been declining.
04/12/24	Regeneron (REGN) Accused of Fraudulent Practices Related to Eylea

REGN Chatroom

briefingcom Posted - 1 hour ago

$REGN: Regeneron Pharma and Mammoth Biosciences announce a collaboration to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20240425070812REGN&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page

Stock_Titan Posted - 4 hours ago

$REGN Regeneron and Mammoth Biosciences Collaborate to Pursue Next-Generation CRISPR-Based Gene Editing for Multiple Diseases https://www.stocktitan.net/news/REGN/regeneron-and-mammoth-biosciences-collaborate-to-pursue-next-1ot81nrlzajk.html

Stock_Titan Posted - 1 day ago

$REGN Regeneron to Showcase Progress in Advancing Novel Investigational Treatment Approaches for a Broad Range of Solid Tumors and Blood Cancers at ASCO https://www.stocktitan.net/news/REGN/regeneron-to-showcase-progress-in-advancing-novel-investigational-r24b3e01m9vx.html

ntlaguy Posted - 1 day ago

$REGN $NTLA Podcast posted today https://www.bio.org/podcast/editing-cells-within-body-new-crispr-frontier?mkt_tok=NDkwLUVIWi05OTkAAAGSqkFdzRzyz9pbCkpu7l2fP_Za4fJlAx-kQ3iVGRyNSKU9RJtUwgBfXCmMBi2kSQuws42iNbUqtpX_hpbp0votHUSj2E2lJlsSCw38mHmXa4ga

ntlaguy Posted - 1 day ago

$NTLA $REGN Patent granted today.

ntlaguy Posted - 1 day ago

$REGN $NTLA This was just posted today. Hemophilia B gene editing trial is up and running. They will start enrolling patients in July 2024.

Stock_Titan Posted - 2 days ago

$REGN Regeneron to Highlight Advances in Genetic Medicine Research at American Society of Gene and Cell Therapy (ASGCT) https://www.stocktitan.net/news/REGN/regeneron-to-highlight-advances-in-genetic-medicine-research-at-tl4lwhmlzswm.html

lageorges Posted - 3 days ago

@ians @RinseX3 @DG20 if that argument holds true then i would think Regeneron $REGN would be the best suitor

Tr4648 Posted - 4 days ago

The current stock price is incredibly undervalued. ESPR will be the next $REGN the upside is north of $50 in 2027. 25% royalties from Partner #Daiichisankyo has over 200k scripts, anticipates $8BILL yearly Quote C. Michael Gibson MD @CMichaelGibson · Apr 19 Dr. Cho and I review multiple analyses from the Clear Outcomes Study presented at ACC 2024 including those regarding Gender, Hispanic and Obesity s/b Esperion

themarker Posted - 6 days ago

Cathie Wood and Ark Invest's trade activity from 2024/04/18 $CAT $EXAS $NU $REGN

jonnycbad Posted - 6 days ago

$REGN selling is wild, Eyelea is a cash cow and they just came out with Eyelea HD.

Whiskeyunderthebed Posted - 6 days ago

$REGN I like the AH pricing right now...$925.00

erevnon Posted - 1 week ago

Cantor Fitzgerald reiterates Regeneron Pharmaceuticals $REGN at Neutral and maintains a price target of https://marketsblock.com/stock-upgrades-and-downgrades/

Intergalactic_Portfolio Posted - 1 week ago

$REGN Some clown slapping the ask with 1 share buys.

Intergalactic_Portfolio Posted - 1 week ago

$REGN What’s the after hours volume?

Whiskeyunderthebed Posted - 1 week ago

$REGN

GermanBulle Posted - 1 week ago

$INO is that the $REGN news we are all waiting for. Low entry in a future multi billion dollar company. Time and more details will till us the real truth behind that crazy news. More 2 come

iSwag Posted - 1 week ago

$CDTX Monday am discount price tags. Its DFC platform will be a game changer - Tick tock ⏳⌛️ $SPY $XBI $REGN $CRSP

ProKnifeCatcher87 Posted - 1 week ago

$REGN 945

ProKnifeCatcher87 Posted - 1 week ago

$LLY not buying even if goes down cause people no longer want to lose weight or check their diabetes or see clearly or maintain their health , cause of drones 🙄😵‍💫 $REGN $AMGN $IBB $QQQ

OG_Lotus Posted - 1 week ago

$REGN gonna tell me I’m ignorant as the price moves directly toward my expectations 😂😂😂. My offers and full value are private buddy. This account only gets the edge of my immediate thoughts that end up revised most of the time anyways. Nothing posted on this acct matters, speak directly to me for proper information Thank u

UncleStock Posted - 1 week ago

$HRMY $CPRX $REGN suggested for #raremetals - value screen: https://zpr.io/g2sfw

clarkkant Posted - 1 week ago

$GL Nobody knows what allegations are true or not. The fact is though, not one Panda Express report has ever resulted in a DOJ or SEC investigation. Look at $REGN got an announcement the DOJ was investigating fraud price fixing under FCA and it took what a -5% haircut Thursday? Just some thoughts.

Aigner_Andreas Posted - 1 week ago

TD BUY $REGN at 904.70, Supp 904.70 Resis 969.31 R7 HiLo 71% T1Y 776 buy 2.4 DIV N/A #Regeneron #stocks #trading #finance #market

OG_Lotus Posted - 1 week ago

$REGN way more

ProKnifeCatcher87 Posted - 1 week ago

$REGN Gift 🎁 thankyou Added $200k in 401 today Have had position since 2011 in 60 area Ready to retire on this soon $1500 value $AMGN $IBB $LLY

erevnon Posted - 1 week ago

B of A Securities maintains Regeneron Pharmaceuticals $REGN at Underperform and raises the price target from $710 to https://marketsblock.com/stock-upgrades-and-downgrades/

MaHTN Posted - 1 week ago

$REGN never but stock in a company that cheats ASP …they knew what they were doing. #tickingtimebomb

Stocksrunner Posted - 1 week ago

$REGN now sports an oversold RSI. Time to separate the market mood from the melody! 🎶📉 https://stocksrunner.com/symbol/REGN

ProKnifeCatcher87 Posted - 1 week ago

$REGN politicians are crooked Shame Shame Shame on them This is a life saving game changing company Thankyou for the dip !!! Added $235k to 401 today $VRTX $AMGN

Analyst Ratings

TD Cowen	Buy	Apr 24, 24
Cantor Fitzgerald	Neutral	Apr 17, 24
UBS	Buy	Apr 17, 24
Cantor Fitzgerald	Neutral	Apr 15, 24
B of A Securities	Underperform	Apr 12, 24
RBC Capital	Outperform	Apr 9, 24
Truist Securities	Buy	Apr 3, 24
Truist Securities	Buy	Mar 26, 24
Morgan Stanley	Overweight	Mar 13, 24

Insider Trades	Relationship	Date	Transactions	Cost($)	#Shares	Value($)	#Share Own	SEC Form 4
STAHL NEIL	EVP Research and Dev.. EVP Research and Development	Feb 02	Option	399.66	30,750	12,289,545	82,769	02/06/24
Landry Robert E	EVP Finance CFO EVP Finance CFO	Feb 02	Option	378.98	400	151,592	23,974	02/06/24
McCourt Marion	EVP Commercial EVP Commercial	Feb 05	Sell	934.71	1,000	934,710	13,789	02/06/24
Bassler Bonnie L	Director Director	Jan 30	Sell	959	827	793,093	1,382	01/31/24
Bassler Bonnie L	Director Director	Jan 30	Option	380.95	827	315,046	2,209	01/31/24
Landry Robert E	EVP Finance CFO EVP Finance CFO	Jan 12	Option	378.98	800	303,184	23,406	01/17/24
RYAN ARTHUR F	Director Director	Nov 07	Sell	828.9	100	82,890	18,547	11/08/23
Bassler Bonnie L	Director Director	Aug 10	Sell	789	853	673,017	1,247	08/11/23
Bassler Bonnie L	Director Director	Aug 10	Option	391.92	853	334,308	2,100	08/11/23
McCourt Marion	EVP Commercial EVP Commercial	Aug 01	Sell	744.66	250	186,165	20,053	08/03/23
VAGELOS P ROY	Director Director	Feb 22	Option	270.43	42,500	11,493,275	366,583	02/24/23
Landry Robert E	EVP Finance CFO EVP Finance CFO	Oct 31	Sell	757.9	482	365,308	28,744	11/02/22
Landry Robert E	EVP Finance CFO EVP Finance CFO	Oct 31	Option	381.92	2,000	763,840	30,744	11/02/22
McCourt Marion	EVP Commercial EVP Commercial	Nov 01	Option	372.46	1,100	409,706	20,744	11/02/22
McCourt Marion	EVP Commercial EVP Commercial	Nov 01	Sell	750	1,100	825,000	19,644	11/02/22
Tessier-Lavigne Marc	Director Director	Sep 29	Option	413.33	10,838	4,479,671	5,881	10/03/22
Tessier-Lavigne Marc	Director Director	Sep 29	Sell	696.44	10,838	7,548,017	2,269	10/03/22
Bassler Bonnie L	Director Director	Sep 08	Option	386.84	3,167	1,225,122	1,691	09/12/22
Bassler Bonnie L	Director Director	Sep 08	Sell	711	3,167	2,251,737	1,082	09/12/22
LAROSA JOSEPH J	EVP General Counsel.. EVP General Counsel and Secret	Sep 09	Option	270.43	30,000	8,112,900	41,580	09/12/22
RYAN ARTHUR F	Director Director	Aug 04	Option	412.58	10,453	4,312,699	21,092	08/08/22
RYAN ARTHUR F	Director Director	Aug 04	Sell	621.48	10,453	6,496,330	19,682	08/08/22
STAHL NEIL	EVP Research and Dev.. EVP Research and Development	Aug 04	Option	270.43	95,000	25,690,850	147,795	08/08/22
STAHL NEIL	EVP Research and Dev.. EVP Research and Development	Aug 04	Sell	613.95	23,782	14,600,959	52,795	08/08/22
RYAN ARTHUR F	Director Director	May 02	Sell	650.58	100	65,058	22,182	05/03/22
McCourt Marion	EVP Commercial EVP Commercial	May 02	Option	342.93	1,100	377,223	20,744	05/03/22
McCourt Marion	EVP Commercial EVP Commercial	May 02	Sell	656.97	1,100	722,667	19,644	05/03/22
Landry Robert E	EVP Finance CFO EVP Finance CFO	Apr 07	Option	393.75	9,500	3,740,625	32,158	04/11/22
Landry Robert E	EVP Finance CFO EVP Finance CFO	Apr 07	Sell	735.54	2,187	1,608,626	28,744	04/11/22
LAROSA JOSEPH J	EVP General Counsel.. EVP General Counsel and Secret	Apr 07	Sell	721.1	5,114	3,687,705	16,900	04/11/22
Fenimore Christopher R.	SVP Controller SVP Controller	Apr 08	Option	413.05	7,450	3,077,222	30,066	04/11/22
Bassler Bonnie L	Director Director	Apr 07	Option	380.95	1,240	472,378	2,322	04/11/22
Bassler Bonnie L	Director Director	Apr 07	Sell	725	1,240	899,000	1,082	04/11/22
Landry Robert E	EVP Finance CFO EVP Finance CFO	Mar 28	Option	462.06	14,500	6,699,870	34,212	03/30/22
Landry Robert E	EVP Finance CFO EVP Finance CFO	Mar 28	Sell	688.04	2,683	1,846,011	28,744	03/30/22
Van Plew Daniel P	EVP & General Mgr, I.. EVP & General Mgr, Industrial	Feb 22	Option	399.66	40,000	15,986,400	70,578	02/24/22
Van Plew Daniel P	EVP & General Mgr, I.. EVP & General Mgr, Industrial	Feb 22	Sell	612.92	6,781	4,156,211	30,578	02/24/22
BROWN MICHAEL S	Director Director	Feb 23	Sell	608.68	500	304,340	7,162	02/24/22
MURPHY ANDREW J	EVP Research EVP Research	Feb 14	Option	179.13	10,000	1,791,300	68,470	02/16/22
MURPHY ANDREW J	EVP Research EVP Research	Feb 14	Sell	629.34	3,540	2,227,864	58,470	02/16/22
MURPHY ANDREW J	EVP Research EVP Research	Dec 08	Option	52.03	16,500	858,495	75,667	12/10/21
MURPHY ANDREW J	EVP Research EVP Research	Dec 08	Sell	664.97	7,122	4,735,916	59,167	12/10/21
Tessier-Lavigne Marc	Director Director	Dec 09	Option	371.4	3,784	1,405,378	5,862	12/10/21
Tessier-Lavigne Marc	Director Director	Dec 09	Sell	665	3,784	2,516,360	2,078	12/10/21
Landry Robert E	EVP Finance CFO EVP Finance CFO	Dec 08	Option	399.66	4,250	1,698,555	34,207	12/10/21
Landry Robert E	EVP Finance CFO EVP Finance CFO	Dec 08	Sell	664.66	781	519,099	29,957	12/10/21
LAROSA JOSEPH J	EVP General Counsel.. EVP General Counsel and Secret	Dec 08	Option	179.13	30,000	5,373,900	46,520	12/10/21
SCHLEIFER LEONARD S	President & CEO President & CEO	Nov 19	Option	224.78	520,313	116,955,956	651,568	11/19/21
BROWN MICHAEL S	Director Director	Jan 27	Option	380.95	2,480	944,756	3,371	01/27/21
BROWN MICHAEL S	Director Director	Jan 27	Sell	554.32	2,480	1,374,714	891	01/27/21